AnaptysBio Inc
$ 67.51
0.91%
17 Apr - close price
- Market Cap 1,923,258,000 USD
- Current Price $ 67.51
- High / Low $ 68.73 / 65.69
- Stock P/E N/A
- Book Value 1.33
- EPS -0.46
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE -0.24 %
- 52 Week High 73.30
- 52 Week Low 17.11
About
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Analyst Target Price
$79.91
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-09 | 2025-11-04 | 2025-08-07 | 2025-05-07 | 2025-03-10 | 2024-11-08 | 2024-08-05 | 2024-05-09 | 2024-03-11 | 2023-11-02 | 2023-08-07 | 2023-05-11 |
| Reported EPS | 1.58 | 0.52 | -1.34 | -1.28 | -0.72 | -1.14 | -1.71 | -1.64 | -1.59 | -1.41 | -1.5 | -1.58 |
| Estimated EPS | 0.8726 | -1.4 | -1.52 | -1.56 | -1.7049 | -1.65 | -0.99 | -1.57 | -1.6 | -1.79 | -1.7 | -1.05 |
| Surprise | 0.7074 | 1.92 | 0.18 | 0.28 | 0.9849 | 0.51 | -0.72 | -0.07 | 0.01 | 0.38 | 0.2 | -0.53 |
| Surprise Percentage | 81.0681% | 137.1429% | 11.8421% | 17.9487% | 57.7688% | 30.9091% | -72.7273% | -4.4586% | 0.625% | 21.2291% | 11.7647% | -50.4762% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.77 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANAB
2026-04-14 09:23:00
JPMorgan Chase significantly reduced its stake in AnaptysBio, a clinical-stage immunology company, during the third quarter of 2026 by selling over 94% of its shares. This substantial divestment by a major institutional investor could indicate a shift in market sentiment regarding AnaptysBio, which focuses on developing antibody treatments for immunological and inflammatory disorders. News of the sell-off was disclosed in a 13F filing published on April 14, 2026.
2026-04-10 23:09:02
This article provides a technical analysis of ANAPTYSBIO INC- W/I (NASDAQ:ANABV), detailing its overall market performance, trend indicators, and chart patterns. The stock received a low technical rating of 1 out of 10, indicating below-average performance with negative short-term and medium-term signs. Key indicators like RSI suggest the stock is overbought, while MACD shows a positive trend, creating a mixed technical picture.
2026-04-10 22:39:19
The article provides a stock overview for ANAPTYSBIO INC- W/I (NASDAQ:ANABV), showing its current price at $46.87, up 5.33% today. It details key statistics, performance, financial highlights, and ownership information. The company currently has a ChartMill Technical rating of 1 out of 10 and does not pay a dividend.
2026-04-10 17:10:16
This article provides the stock chart for ANAPTYSBIO INC- W/I (NASDAQ:ANABV) from ChartMill.com. It displays the current stock price and links to various security analysis tools. The chart shows the daily performance of ANABV.
2026-04-10 10:39:05
AnaptysBio (ANAB) stock has reached a new 52-week high of $68.46, marking a 320.01% gain over the past year. The biotechnology firm has a market capitalization of $1.96 billion, with positive market sentiment driven by recent corporate restructuring, including an upcoming spin-off of First Tracks Biotherapeutics and a $100 million stock repurchase plan. Despite this performance, InvestingPro suggests the stock may be overvalued relative to its Fair Value.
2026-04-09 19:39:35
AnaptysBio (NASDAQ:ANAB) recently hit a new 52-week high of $68.62, maintaining a "Moderate Buy" consensus rating from analysts with an average target price of $80.10. Despite beating quarterly revenue and EPS estimates, the company remains unprofitable. The board approved a stock buyback plan, even as several insiders, including the CEO, have sold shares.
